THNR Fact Sheet: Amplify Weight Loss Drug & Treatment ETF
Share
$24.26
close, Nov 20, 2026
Over the year to Nov 19, 2026, THNR returned −0.1% in total and charged 0.59% a year.
- 1-year total return
- −1.3%
- to Nov 20, 2026
- Expense ratio
- 0.59%
- a year
- Net assets
- $4.9m
- on Nov 19, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
THNR $9,986 −0.1% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−2.7%
3 months−11.9%
Year to date−3.8%
1 year−1.3%
Since launch−2.0%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Eli Lilly & Co11.94%
Novo Nordisk A/S8.75%
Regeneron Pharmaceuticals Inc6.15%
Amgen Inc6.03%
Gilead Sciences Inc5.91%
Roche Holding AG5.87%
AstraZeneca PLC5.81%
AbbVie Inc5.72%
Chugai Pharmaceutical Co Ltd5.52%
Pfizer Inc5.26%
THNR top ten by weight, 67.0% of the fund, of its 21 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 21 stocks in healthcare innovation and GLP-1, 46% of its weight in S&P 500 companies · First traded May 21, 2024 · Benchmark Its own holdings, as of Nov 19, 2026